Research interests include Attention Deficit Hyperactivity Disorder, CAR-T cell therapy research, Virus-based gene therapy research, and Surfactants and Colloidal Systems.
895P Phase I study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody MIL62 in Chinese patients with relapsed/refractory CD20-positive B-cell non-Hodgkin’s lymphoma
Annals of Oncology2020cited by 2position: middledoi